Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

---
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
Vote:
0 0
Previous GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
Next Xinhua Silk Road: Posidonia China Night provides high-level platform for int'l maritime exchange, cooperation

Related News

Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA

Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

menu
menu